Andere talen Camurus AB

Aandelen

CAMX

SE0007692850

Beurs gesloten - Nasdaq Stockholm Andere beurzen 17:29:32 31-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
581 ^SEK	+7,89%		+3,66%	+7,99%

23/05	Camurus' geneesmiddel voor zeldzame groeistoornis geaccepteerd voor beoordeling in EU	MT
23/05	Camurus ontvangt goedkeuring van EMA voor de MAA-aanvraag voor Octreotide SC Depot (Cam2029) voor de behandeling van acromegalie	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Camurus' Rare Growth Disorder Drug Accepted for Review in EU	23/05
Camurus Receives EMA Acceptance of MAA Filing for Octreotide SC Depot for the Treatment of Acromegaly	23/05
Transcript : Camurus AB, Q1 2024 Earnings Call, May 08, 2024	08/05
Camurus AB Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Camurus AB Announces Board Resignations	02/04
Camurus' New Drug Application for Acromegaly Treatment Accepted by US FDA	05/03
Camurus AB Announces FDA Acceptance of NDA Submission for Oclaiz? for Treatment of Acromegaly	05/03
Camurus AB Reports Earnings Results for the Full Year Ended December 31, 2023	15/02
Transcript : Camurus AB, 2023 Earnings Call, Feb 15, 2024	15/02
Camurus AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15/02
Camurus AB Provides Earnings Guidance for the Full Year 2024	15/02
Camurus AB Appoints Behshad Sheldon as President of Camurus Inc. and Member of the it's Executive Management Team, Starting 1 April 2024	13/02
Camurus AB Completes Enrollment in the POSITANO Study of CAM2029 in Patients with Polycystic Liver Disease	08/02
Camurus Submits US FDA New Drug Application for Hormonal Disorder Treatment	21/12
Camurus AB Submits New Drug Application to the US FDA for Oclaiz for Treatment of Acromegaly	21/12
Camurus to Trade on Nasdaq Stockholm's Large Cap Segment	20/12
Camurus Concludes Enrollment in Phase 3 Study of Neuroendocrine Tumors Vaccine	14/12
Camurus AB Announces Completed Enrollment in the Phase 3 SORENTO Study of CAM2029 in Patients with Neuroendocrine Tumors	14/12
Transcript : Camurus AB, Q3 2023 Earnings Call, Nov 09, 2023	09/11
Camurus AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Camurus AB

Aandelen

CAMX

SE0007692850

Andere talen

Filters